

David C Fajgenbaum

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5921384/david-c-fajgenbaum-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68
papers

2,473
citations

21
h-index

49
g-index

80
ext. papers

3,856
ext. citations

7.9
avg, IF

6.52
L-index

#	Paper	IF	Citations
68	A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9	1.9	0
67	Bone Marrow Findings of Idiopathic Multicentric Castleman Disease: A Histopathologic Analysis and Systematic Literature Review.. <i>Hematological Oncology</i> , 2022 ,	1.3	1
66	Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. <i>New England Journal of Medicine</i> , 2022 , 386, 2036-2048	59.2	0
65	Chasing My Cure: Lessons Learned from My Rare Illness 2022 , 3-9		
64	Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply. <i>Rheumatology</i> , 2021 , 60, e76-e77 ³⁻⁹		
63	Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease. <i>Blood</i> , 2021 , 138, 2696-2696	2.2	0
62	Ongoing Symptoms and Reduced Health Measures in Unicentric Castleman Disease Patients Despite Perceived-to-be Curative Surgical Excision. <i>Blood</i> , 2021 , 138, 2709-2709	2.2	
61	Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity. <i>Blood</i> , 2021 , 138, 4004-4004	2.2	
60	Castleman disease. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 84	51.1	3
59	Emerging role of 18F-FDG PET/CT in Castleman disease: a review. <i>Insights Into Imaging</i> , 2021 , 12, 35	5.6	7
58	Adrenalitis and anasarca in idiopathic multicentric Castleman disease. <i>Lancet, The</i> , 2021 , 397, 1749	40	2
57	Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7048-7048	2.2	3
56	DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	5
55	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 240	12.8	0
54	Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2021 , 96, 1241-1252	7.1	9
53	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 419-430	5.3	18
52	HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. <i>Rheumatology</i> , 2021 , 60, e3-e4	3.9	3

51	UCD with MCD-like inflammatory state: surgical excision is highly effective. <i>Blood Advances</i> , 2021 , 5, 122-128	7.8	1
50	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2021 , 5, 3445-3456	7.8	2
49	Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy. <i>Blood Advances</i> , 2021 ,	7.8	1
48	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. <i>European Journal of Haematology</i> , 2021 , 107, 642-649	3.8	1
47	TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. <i>Case Reports in Oncology</i> , 2021 , 14, 1359-1365	1	0
46	Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	6
45	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. <i>Blood Advances</i> , 2020 , 4, 6039-6050	7.8	24
44	Increased mTOR activation in idiopathic multicentric Castleman disease. <i>Blood</i> , 2020 , 135, 1673-1684	2.2	24
43	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 435-449	6.2	35
42	AA amyloidosis associated with Castleman disease: A case report and review of the literature. <i>Medicine (United States)</i> , 2020 , 99, e18978	1.8	0
41	Genetic basis for iMCD-TAFRO. <i>Oncogene</i> , 2020 , 39, 3218-3225	9.2	6
40	Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. <i>JCI Insight</i> , 2020 , 5,	9.9	13
39	Castleman Disease. <i>Rare Diseases of the Immune System</i> , 2020 , 215-228	0.2	
38	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020 , 1, 100158	18	5
37	Cytokine Storm. <i>New England Journal of Medicine</i> , 2020 , 383, 2255-2273	59.2	757
36	Teaching Old Drugs New Tricks: Statins for COVID-19?. <i>Cell Metabolism</i> , 2020 , 32, 145-147	24.6	22
35	Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. <i>Clinical Chemistry</i> , 2020 , 66, 1378-1379	5.5	
34	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020 , 95, 1553-1561	7.1	9

33	Overview of Castleman disease. <i>Blood</i> , 2020 , 135, 1353-1364	2.2	71
32	Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2019 , 10, 1489	8.4	13
31	Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. <i>Blood</i> , 2019 , 133, 1720-1728	2.2	21
30	Letter to the editor regarding Non-cirrhotic portal hypertension associated with multicentric Castleman disease: a case report. <i>Acta Oncologica</i> , 2019 , 58, 515-517	3.2	1
29	Quantitative analysis of a rare disease network international contact database and E-repository provides insights into biobanking in the electronic consent era. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 173	4.2	1
28	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. <i>PLoS ONE</i> , 2019 , 14, e0218660	3.7	10
27	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4451-4463	15.9	48
26	The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. <i>Emerging Topics in Life Sciences</i> , 2019 , 3, 97-105	3.5	3
25	Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. <i>British Journal of Haematology</i> , 2019 , 184, 232-241	4.5	21
24	Plasma proteomics identifies a chemokine storm in idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2018 , 93, 902-912	7.1	33
23	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. <i>Annals of Hematology</i> , 2018 , 97, 1641-1647	3	7
22	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. <i>Current Research in Translational Medicine</i> , 2018 , 66, 83-86	3.7	6
21	Castleman Disease Pathogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 11-21	3.1	43
20	The full spectrum of Castleman disease: 273 patients studied over 20 years. <i>British Journal of Haematology</i> , 2018 , 180, 206-216	4.5	71
19	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2323-2330	2.2	47
18	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , 2018 , 5, 306	4.9	15
17	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2115-2124	2.2	127
16	A novel mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. <i>Blood Advances</i> , 2018 , 2, 2959-2963	7.8	8

15	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 318-325	3.1	5
14	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017 , 129, 1646-1657	2.2	234
13	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. <i>Blood</i> , 2017 , 129, 1658-1668	2.2	88
12	Leveraging information and collaboration to cure disease. <i>Information Services and Use</i> , 2017 , 37, 307-310.5	1.5	
11	TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. <i>Bosnian Journal of Basic Medical Sciences</i> , 2017 , 17, 81-84	3.3	16
10	Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome. <i>Annals of Hematology</i> , 2017 , 96, 497-500	3	6
9	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. <i>Frontiers in Medicine</i> , 2017 , 4, 149	4.9	20
8	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. <i>Immunotherapy</i> , 2016 , 8, 17-26	3.8	18
7	Idiopathic multicentric Castleman disease: a systematic literature review. <i>Lancet Haematology, the</i> , 2016 , 3, e163-75	14.6	152
6	The collaborative network approach: a new framework to accelerate Castleman disease and other rare disease research. <i>Lancet Haematology, the</i> , 2016 , 3, e150-2	14.6	30
5	Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. <i>American Journal of Hematology</i> , 2016 , 91, 220-6	7.1	153
4	A Rare Disease That Picked the Wrong Family: Fighting Back to Help a Loved One and as a Tool for Actively Coping. <i>Death Studies</i> , 2015 , 39, 673-676	3.9	
3	Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. <i>Yale Journal of Biology and Medicine</i> , 2015 , 88, 383-8	2.4	4
2	HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. <i>Blood</i> , 2014 , 123, 2924-33	2.2	208
1	Eruptive cherry hemangiomas associated with multicentric Castleman disease: a case report and diagnostic clue. <i>JAMA Dermatology</i> , 2013 , 149, 204-8	5.1	35